Department of Radiology
Nuclear Medicine Residency Programs
Letter from Chairman
|
About TJU
|
About TJUH
|
Salary
|
Benefits
|
Life at Jeff
|
Diagnostic Radiology
|
Nuclear Medicine
|
Residency Manual
|
Current Residents
Resident Perks
|
The Nuclear Medicine Residency consists of both a one-year and two-year program, which fulfills all of the requirements of the American Board of Nuclear Medicine. The two-year program is targeted to trainees having at least one year of clinical training in other medical specialties. The one-year program is open to individuals who have completed four years of a general radiology residency in any ACGME-accredited program. Both programs qualify residents for certification by the American Board of Nuclear Medicine. Extensive training is provided in all areas of both nuclear imaging and therapy, particularly SPECT imaging and I-131 therapy. There is a strong emphasis on general nuclear medicine, cardiovascular nuclear medicine, oncologic nuclear medicine, and neuro-nuclear medicine. Radionuclide functional studies of every major organ system are performed, including tumor imaging with radiolabeled peptides and monoclonal antibodies, as well as infection imaging with radiolabeled leukocytes. A dedicated PET/CT scanner is housed in the outpatient center. There are ample opportunities for basic and clinical research. The Division works closely with specialists in many clinical departments such as Medicine, Surgery, Neurology, Neurosurgery, Radiation Oncology, and Pediatrics.
Letter from
Vijay M. Rao, M.D.
David C. Levin Professor & Chair, Department of Radiology
Levon Nazarian, M.D.
Residency Program Director
Director of Residency Selection
1087 Main Building
132 S. 10th Street
Philadelphia, PA 19107
Phone: 215-955-7264
We participate in the National Residency Match Program and utilize the Electronic Residency Application Service (ERAS).
Apply NowRecent Publications
Trends in the utilization of outpatient advanced imaging after the deficit reduction act
Safety of iodinated intravenous contrast medium administration in sickle cell disease

